• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, April 17, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Nature: new compound for male contraceptive pill

Bioengineer by Bioengineer
March 3, 2021
in Chemistry
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Dr. Wei Yan discovered a natural compound that exhibits almost ideal male contraceptive effects in pre-clinical studies

IMAGE

Credit: The Lundquist Institute

  • Nature Communications Publishes Paper by Lundquist Institute Investigator Dr. Wei Yan and Colleagues on New Promising Compound for Male Contraceptive Pill
  • The Lundquist Institute researchers discovered a natural compound that exhibits almost ideal male contraceptive effects in pre-clinical studies

LOS ANGELES (March 3, 2021) — In a new paper published by Nature Communications, The Lundquist Institute (TLI) Investigator Wei Yan, MD, PhD, and his research colleagues spell out an innovative strategy that has led to the discovery of a natural compound as a safe, effective and reversible male contraceptive agent in pre-clinical animal models. Despite tremendous efforts over the past decades, the progress in developing non-hormonal male contraceptives has been very limited.

The compound is triptonide, which can be either purified from a Chinese herb called Tripterygium Wilfordii Hook F, or produced through chemical synthesis. Single daily oral doses of triptonide induce altered sperm having minimal or no forward motility with close to 100% penetrance and consequently male infertility in 3-4 and 5-6 weeks. Once the treatment is stopped, the males become fertile again in ~4-6 weeks, and can produce healthy offspring. No discernable toxic effects were detected in either short- or long-term triptonide treatment. All of their data suggest that triptonide is a highly promising non-hormonal male contraceptive agent for men because it appears to meet all of the criteria for a viable contraceptive drug candidate, including bioavailability, efficacy, reversibility and safety. A battery of biochemical analyses suggest that triptonide targets one of the last steps during sperm assembly, leading to the production of altered sperm without vigorous motility required for fertilization.

“Thanks to decades of basic research, which inspired us to develop the idea that a compound that targets a protein critical for the last several steps of sperm assembly would lead to the production of nonfunctional sperm without causing severe depletion of testicular cells”, said Dr. Yan. “We are very excited that the new idea worked and that this compound appears to be an ideal male contraceptive. Our results using non-injurious studies on lower primates suggest triptonide will be an effective treatment for human males as well. Hopefully, we will be able to start human clinical trials soon to make the non-hormonal male contraceptive a reality.”

“Dr. Yan’s discovery represents a major leap forward in the field”, said Drs. Christina Wang and Ronald Swerdloff, who are TLI co-Principal Investigators helping lead NIH-supported advanced clinical trials on hormone-based birth control approaches. “The more contraceptive methods available, the better, as we will want a family of pharmaceutical products to safely and effectively meet the family planning needs of men and couples at different stages of their reproductive lives, with differing ethnic, cultural and religious backgrounds and economic means,” emphasized Wang and Swerdloff.

###

Media Contact for The Lundquist Institute:

Max Benavidez
[email protected]
310-200-2682

About The Lundquist Institute: Research with reach

The Lundquist Institute is an engine of innovation with a global reach and a 69-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and the development of a new 15-acre business tech park, the Lundquist Institute serves as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous, and often fatal orphan diseases.

Media Contact
MAX BENAVIDEZ
[email protected]

Related Journal Article

http://dx.doi.org/10.1038/s41467-021-21517-5

Tags: BiochemistryClinical TrialsDevelopmental/Reproductive BiologyFertilityGynecologyMedicine/HealthPopulation Biology
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

The fate of the planet

April 16, 2021
IMAGE

The future of particle accelerators is here

April 16, 2021

Scientists may detect signs of extraterrestrial life in the next 5 to 10 years

April 16, 2021

On the pulse of pulsars and polar light

April 16, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Jonathan Wall receives $1.79 million to develop new amyloidosis treatment

    60 shares
    Share 24 Tweet 15
  • Terahertz accelerates beyond 5G towards 6G

    852 shares
    Share 341 Tweet 213
  • A sturdier spike protein explains the faster spread of coronavirus variants

    44 shares
    Share 18 Tweet 11
  • UofL, Medtronic to develop epidural stimulation algorithms for spinal cord injury

    56 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

University of WashingtonVaccineWeather/StormsVirusVirologyWeaponryVaccinesUrbanizationVehiclesUrogenital SystemZoology/Veterinary ScienceViolence/Criminals

Recent Posts

  • New amphibious centipede species discovered in Okinawa and Taiwan
  • USU researchers develop power converter for long-distance, underwater electric grids
  • The fate of the planet
  • The future of particle accelerators is here
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In